Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer

Overexpression of breast cancer resistance protein (BCRP) has been shown to produce multidrug resistance (MDR) in colon cancer, leading to major obstacles for chemotherapy. In this study, we evaluated the effect of regorafenib, an oral multi-kinase inhibitor, in inhibiting BCRP-mediated MDR in silic...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Lett
Glavni autori: Zhang, Yun-Kai, Wang, Yi-Jun, Lei, Zi-Ning, Zhang, Guan-Nan, Zhang, Xiao-Yu, Wang, De-shen, Al-Rihani, Sweilem B., Shukla, Suneet, Ambudkar, Suresh V., Kaddoumi, Amal, Shi, Zhi, Chen, Zhe-Sheng
Format: Artigo
Jezik:Inglês
Izdano: 2018
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8148022/
https://ncbi.nlm.nih.gov/pubmed/30392788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.canlet.2018.10.032
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items